Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome

QJM: An International Journal of Medicine

Volumn 94, Issue 6, 2001, Pages 293-300

  Suzuki, H ^a   Stanley, A J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE 2 ACETIC ACID; ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATRIAL NATRIURETIC FACTOR; DIURETIC AGENT; DOCARPAMINE; DOPAMINE; FUROSEMIDE; MIDODRINE; MISOPROSTOL; MOZAVAPTAN; NIRAVOLINE; NORADRENALIN; OCTREOTIDE; OPC 3126; ORNIPRESSIN; PROSTAGLANDIN DERIVATIVE; SODIUM; SPIRONOLACTONE; TERLIPRESSIN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

ASCITES; CIRCULATION; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DIURESIS; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; ISCHEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NATRIURESIS; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; SODIUM RESTRICTION; SPLANCHNIC NERVE; SURVIVAL;

EID: 0034949374     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/94.6.293     Document Type: Review

References (83)

1. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
2. Survival and prognostic factors of cirrhotic patients with ascites: A study of 134 outpatients
3. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
4. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites
5. Recovery from hepatorenal syndrome after orthotopic liver transplantation
6. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome: Evidence for the functional nature of renal failure in advanced cirrhosis
7. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites
8. Randomized comparative study of therapeutic paracentesis with and without albumin in cirrhosis
9. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites
10. Effects of therapeutic paracentesis on systemic and hepatic haemodynamics and on renal and hormonal function
11. Single, total paracentesis for tense ascites: Sequential hemodynamic changes and right atrial size
12. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites
13. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: A randomized controlled trial
14. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites
15. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites
16. Postparacentesis plasma expansion prevents asymptomatic laboratory abnormalities, but does it have any impact on morbidity or mortality?
17. Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: A randomized controlled study
18. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis: Results of a randomized study
19. Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites: Results of a randomized study
20. Randomized comparative study of haemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites
21. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis
22. Large-volume paracentesis and intravenous saline: Effects on the renin-angiotensin system
23. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis
24. Transjugular intrahepatic portosystemic shunts (TIPS): A decade later
25. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt
26. Transjugular intrahepatic portasystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites - A randomized trial
27. Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function
28. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS)
29. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portasystemic shunt for refractory ascites
30. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites
31. Severe ascites: Efficacy of the transjugular intrahepatic portosystemic shunt in treatment
32. Refractory ascites: Mid-term results of treatment with a transjugular intrahepatic portosystemic shunt
33. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites
34. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites
35. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts
36. Determinants of mortality in patients with advanced cirrosis after transjugular intrahepatic portosystemic shunting
37. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites
38. Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis
39. Liver transplantation in patients with previous portasystemic shunt
40. Peritoneovenous shunting for ascites
41. The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites
42. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites
43. The treatment of refractory ascites by the LeVeen shunt: A multi-centre controlled trial
44. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites
45. Peritoneovenous shunts: Lessons learned from an eight-year experience with 70 patients
46. LeVeen vs. Denver peritoneovenous shunts for intractable ascites of cirrhosis: A randomized, prospective trial
47. Poor outcome from peritoneovenous shunts for refractory ascites
48. A prospective randomized trial comparing TIPS and peritoneovenous shunt in the treatment of intractable ascites
49. Effects of ascitic fluid infusion on sodium excretion, blood volume and creatinine clearance in cirrhosis
50. Treatment of ascites by reinfusion of concentrated peritoneal fluid: Review of 318 procedures in 210 patients
51. A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites
52. Reinfusion of concentrated ascitic fluid versus total paracentesis: A randomised prospective trial
53. The effects of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites
54. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites
55. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites: Effect of increasing systemic arterial pressure
56. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites
57. Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis
58. Low-dose dopamine infusion in cirrhosis with refractory ascites
59. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: A pilot study
60. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
61. Aquaretic effects of niravoline, a k-opioid agonist, in patients with cirrhosis
62. Natriuretic effect of an adenosine-1-receptor antagonist in cirrhotic patients with ascites
63. Pathogenesis, diagnosis, and treatment of ascites in cirrhosis
64. 2 in cirrhosis: Relationship to functional renal failure and sodium and water excretion
65. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure
66. 1
67. 1 analogue) and albumin administration
68. Response to dopamine hydrochloride in the hepatorenal syndrome
69. Effects of dopamine on renal function in patients with cirrhosis
70. Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine
71. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis: Effects on renal hemodynamics and atrial natriuretic factor
72. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome
73. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
74. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome
75. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation
76. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine
77. Reversal of type 1 hepatorenal syndrome with the administration of mitodrine and octreotide
78. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients
79. Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt
80. TIPS for hepatorenal syndrome
81. Treatment of hepatorenal syndrome with the transjugular intrahepatic portosystemic shunt (TIPS)
82. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems
83. Long term outcome after transjugular intrahepatic porto-systemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study